Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
25 September 2019 | Story Zamuxolo Feni | Photo Liza Crawley
Read More Photo SANRAL
SANRAL Chief Executive Officer Skhumbuzo Macozoma and UFS Rector and Vice-Chancellor Prof Francis Petersen cutting a cake to mark 10 years of collaboration between the two institutions.

The Science-for-the-Future (S4F) programme is fundamental to generating the required pipeline for technologically skilled entrepreneurs and workers by focusing on Mathematics and Science support to learners, teachers, and parents.

This is according to the South African National Roads Agency Limited (SANRAL) Chief Executive Officer, Skhumbuzo Macozoma, who delivered a keynote address at the Annual Science for the Future Summit held at the University of the Free State (UFS) on 20 September.

The S4F is a partnership between the UFS and SANRAL, with the fundamental purpose to train Maths and Science teachers and to support learners and parents. The programme has now been extended to six other universities, namely Nelson Mandela University and Walter Sisulu University in the Eastern Cape; the University of Limpopo, University of KwaZulu-Natal, and the two recently established universities, the University of Mpumalanga and the Sol Plaatje University in the Northern Cape.

Dr Cobus van Breda, the Programme Director for the UFS S4S, said they developed the Family Math and Key Concepts in Science programmes to address issues that prevent learners from excelling in these critical subjects. It seeks to improve the content knowledge of teachers and provide them with more skills-teaching resources.

Macozoma said: “I am proud and deeply honoured to stand before you today in the strength of a successful 10-year partnership with the University of the Free State which we are celebrating here today, together with the hosting of the Annual Science for the Future Summit.”  More than 300 teachers attended the summit.

Planning for the future

He indicated that SANRAL's long-term strategy, Horizon 2030, instructed the development of a new human-resources strategy for the organisation, which has identified three pillars that underpin SANRAL's human-capital development initiatives, namely people, skills, and performance.

“The strategic opportunities identified by SANRAL include capitalising on the opportunity presented by the digital revolution to create a new generation of technologically skilled entrepreneurs and workers; returning to good and ethical governance in both the public and private sectors; bringing back the prestige of serving the citizens of SA through state institutions: fashioning SANRAL as an employer of the future and delivering technical skills to address the glaring skills gap in engineering and other domains,” he said.

Macozoma stated that SANRAL has also decided to review and rationalise its support to institutions of higher learning in order to grow the footprint of its support programmes, increase the impact, and ensure equity.

Beyond this, he stated that SANRAL wanted to ensure that learners are equipped with fundamental competencies that are essential to complement academic teachings, including critical thinking, creativity, collaboration, communication, information literacy, media literacy, technology literacy, and flexibility.         

Facing 4IR head on

Macozoma said the most important characteristics of the Fourth Industrial Revolution that must be taken into consideration by those who aim to survive it, drive it, and benefit from it, is a smart customer – who is informed and dictates what services he/she wants and how they should be delivered; technology at the fingertips – which will enable rapid, real-time, borderless services to information, services, and technology as an enabler – bringing efficiency to logistics, mobility, medicine, education, industries, the economy, the military, global trade, and politics.  

Working closely with school and society

UFS Rector and Vice-Chancellor, Prof Francis Petersen, said the university has an important responsibility to generate knowledge that will impact society positively.

“We have a role to work closely with our schools and society so that we can understand each other’s needs,” he said.

“We need to strengthen collaboration with all our partners so that we can travel further and make an impact in our society,” said Prof Petersen.

One of the participating teachers in the S4F programme, Grace Molante, from a primary school in Zastron, said: “It is programmes such as these that instil hope in us as teachers. Some learners could find Maths and Science very difficult and challenging subjects, but this programme makes problem solving more enjoyable and practical.”

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept